# US 2016/0257649 A1 · Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257649 A1
- Document ID: US20160257649A1
- Status: Published application
- Kind: A1
- Application number: 14/636,736
- Filed: 2015-03-03
- Published: 2016-09-08
- Earliest claimed: 2015-03-03
- Assignees: Shuttle Pharmaceuticals, Inc.
- Applicants: Shuttle Pharmaceuticals, LLC
- Inventors: Scott Grindrod; Mira Jung; Milton Brown; Anatoly Dritschilo
- Web page: https://patentgrep.com/patent/US20160257649A1

## CPC

- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/00: Radiation therapy (ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00)
- A61P 35/00: Antineoplastic agents
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D 403/14: containing three or more hetero rings
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.

## Claims

### Claim 1

A compound having the formula:
wherein R1, R3, R7, and R8 are independently selected from the group consisting of H, hydroxy, halogen and, optionally substituted, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, heteroaryl, amino, alkoxy, carboxy, carbalkoxy, carboxamido, sulfonyl, sulfinyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosufonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, and dialkylaminosulfinylalkyl;
R2 and R9 are independently selected from the group consisting of H and, optionally substituted, sulfinyl, sulfonyl, alkyl, alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl;
R4 is selected from the group consisting of H and optionally substituted alkyl;
R5 is selected from the group consisting of H, and optionally substituted alkyl and indole;
R6 is selected from the group consisting of H and optionally substituted alkyl;
X is selected from the group consisting of:
wherein R10 is selected from the group consisting of H and, optionally substituted, alkyl, alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl;
n is 0 or 1; r is an integer from 0 to 3; q is an integer from 3 to 10; the dashed line indicates the presence of a single bond or a double bond as allowed; with the proviso that, where X is a substituent other than maleimide or N-carbonylmaleimide and R5 is a substituent other than indole, then R3 is a substituent selected from the group consisting of hydroxy, halogen and, optionally substituted, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, heteroaryl, amino, alkoxy, carboxy, carbalkoxy, carboxamido, sulfonyl, sulfinyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosufonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, and dialkylaminosulfinylalkyl, with the dashed line indicating the presence of a double bond; and the pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein q is an integer from 4 to 6.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound comprises the formula:
wherein R11, R13, R14, and R16 are independently selected from the group consisting of H, hydroxyl, halogen and, optionally substituted, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, heteroaryl, amino, alkoxy, carboxy, carbalkoxy, carboxamido, sulfonyl, sulfinyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosufonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, and dialkylaminosulfinylalkyl;
X is selected from the group consisting of:
wherein R18 is selected from the group consisting of H and, optionally substituted, alkyl, alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl;
R12 and R15 is independently selected from the group consisting of H and, optionally substituted, alkyl, sulfinyl, and sulfonyl;
R17 is selected from the group consisting of H and optionally substituted alkyl;
n is an integer from 3 to 10; the dashed line indicates the presence of a single bond or a double bond as allowed; with the proviso that, where X is amide, then R13 is a substituent selected from the group consisting of hydroxyl, halogen and, optionally substituted, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, heteroaryl, amino, alkoxy, carboxy, carbalkoxy, carboxamido, sulfonyl, sulfinyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, monoalkylaminosufonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, and dialkylaminosulfinylalkyl, when the dashed line indicates the presence of a double bond; and the pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the compound comprises the formula:
and the pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound comprises the formula:
wherein R19 and R21 are independently selected from the group consisting of H, hydroxyl, halogen and, optionally substituted alkyl, aryl, heterocycle, heteroaryl, sulfonyl, sulfinyl, alkoxy, and amino;
X is selected from the group consisting of:
wherein R23 is selected from the group consisting of H and, optionally substituted, alkyl, alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl;
R20 is selected from the group consisting of H and, optionally substituted, alkyl, sulfinyl, and sulfonyl;
R22 is selected from the group consisting of H and optionally substituted alkyl;
r is an integer from 0 to 4; q is an integer from 3 to 10; the dashed line indicates the presence of a single bond or a double bond as allowed; with the proviso that, R21 is 2-alkyl or 3-alkyl with the dashed line indicating the presence of a double bond; and the pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 7)

The compound of claim 7, wherein the compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound comprises the formula:
wherein R24 and R26 are independently selected from the group consisting of H, hydroxyl, halogen and, optionally substituted alkyl, aryl, heterocycle, heteroaryl, sulfonyl, sulfinyl, alkoxy, and amino;
R25 is selected from the group consisting of H and, optionally substituted, alkyl, sulfinyl, and sulfonyl;
R27 is selected from the group consisting of H and optionally substituted alkyl; m may be an integer from 3 to 10; the dashed line may indicate the presence of a single bond or a double bond as allowed; with the proviso that, R26 is a substituent selected from the group consisting of hydroxyl, halogen and, optionally substituted alkyl, aryl, heterocycle, heteroaryl, sulfonyl, sulfinyl, alkoxy, and amino, with the dashed line indicating the presence of a double bond; and the pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 9)

The compound of claim 9, wherein the compound comprises the formula:
and the pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 1)

A pharmaceutical formulation, in unit dosage form, comprising a compound of claim 1 in an amount effective to inhibit histone deacetylase (HDAC) and activate ataxia telangiectasia mutated (ATM) in a patient in need thereof and at least one physiologically compatible carrier medium.

### Claim 12 (depends on 5, 11)

The pharmaceutical formulation of claim 11, comprising a compound of claim 5.

### Claim 13 (depends on 7, 11)

The pharmaceutical formulation of claim 11, comprising a compound of claim 7.

### Claim 14 (depends on 9, 11)

The pharmaceutical formulation of claim 11, comprising a compound of claim 9.

### Claim 15 (depends on 1)

A method of treating a disease in a patient in need thereof, wherein said treatment comprises administering a therapeutically effective amount of at least one compound of claim 1 configured to inhibit histone deacetylase (HDAC) and activate ataxia telangiectasia mutated (ATM).

### Claim 16 (depends on 15)

The method of claim 15, wherein the at least one compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 17 (depends on 5, 15)

The method of claim 15, wherein the at least one compound comprises a compound of claim 5.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 19 (depends on 7, 15)

The method of claim 15, wherein the at least one compound comprises a compound of claim 7.

### Claim 20 (depends on 19)

The method of claim 19, wherein the at least one compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 21 (depends on 9, 15)

The method of claim 15, wherein the at least one compound comprises a compound of claim 9.

### Claim 22 (depends on 21)

The method of claim 21, wherein the at least one compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 23 (depends on 15)

The method of claim 15, wherein the compound is administered in dosage unit form.

### Claim 24 (depends on 23)

The method of claim 23, wherein the dosage unit includes a physiologically compatible carrier medium.

### Claim 25 (depends on 15)

The method of claim 15, wherein the disease is selected from the group consisting of cancer, an immunological disorder, and a neurological disorder.

### Claim 26 (depends on 25)

The method of claim 25, wherein said cancer is selected from the group consisting of gastric cancer, prostate cancer, colon cancer, breast cancer, Non-Hodgkin's lymphoma, ovarian cancer, sarcoma, lung cancer, leukemia, myeloma, testicular cancer, cervical cancer, pancreatic cancer, head and neck cancer, rectal cancer, and brain cancer.

### Claim 27 (depends on 26)

The method of claim 26, further including the step of administering to said patient an amount of radiotherapy configured to treat said cancer.

### Claim 28 (depends on 25)

The method of claim 25, wherein said immunological disorder is selected from the group consisting of systemic lupus and erythematosus rheumatoid arthritis.

### Claim 29 (depends on 25)

The method of claim 25, wherein said neurological disorder is selected from the group consisting of stroke, Huntington's disease, spinal muscular atrophy (SMA), Parkinson's disease, Alzheimer's, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis (ALS).

### Claim 30 (depends on 15)

The method of claim 15, wherein the method is a second line method of treatment for the patient and administration of the compound occurs after performance of a first line therapy on the patient that failed to treat the disease.

### Claim 31 (depends on 15)

The method of claim 15, wherein the method is a third line method of treatment for the patient and administration of the compound occurs after performance of a second line therapy on the patient that failed to treat the disease.

### Claim 32 (depends on 1)

A method of treatment comprising sensitizing cancerous cells to radiotherapy and protecting non-cancerous cells from radiotherapy in a patient in need thereof, wherein cancerous cells are sensitized to radiotherapy by inhibiting histone deacetylase (HDAC) and non-cancerous cells are protected from radiotherapy by activating ataxia telangiectasia mutated (ATM), the method comprising administering a therapeutically effective amount of a compound of claim 1.

### Claim 33 (depends on 32)

The method of claim 32, wherein the compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 34 (depends on 5, 32)

The method of claim 32, wherein the method comprises administering a therapeutically effective amount of a compound of claim 5.

### Claim 35 (depends on 34)

The method of claim 34, wherein the compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 36 (depends on 7, 32)

The method of claim 32, wherein the method comprises administering a therapeutically effective amount of a compound of claim 7.

### Claim 37 (depends on 36)

The method of claim 36, wherein the compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 38 (depends on 1, 32)

The method of claim 32, wherein the method comprises administering a therapeutically effective amount of a compound of claim 1.

### Claim 39 (depends on 38)

The method of claim 38, wherein the compound is selected from the group consisting of:
and the pharmaceutically acceptable salts thereof.

### Claim 40 (depends on 32)

The method of claim 32, wherein the compound is administered in dosage unit form.

### Claim 41 (depends on 40)

The method of claim 40, wherein the dosage unit includes a pharmaceutically compatible carrier medium.

### Claim 42 (depends on 32)

The method of claim 32, wherein the method is a second line method of treatment for the patient and administration of the compound occurs after performance of a first line therapy on the patient that treat the cancerous cells of the patient.

### Claim 43 (depends on 32)

The method of claim 32, wherein the method is a third line method of treatment for the patient and administration of the compound occurs after performance of a second line therapy on the patient that failed to treat the cancer.

### Claim 44 (depends on 32)

The method of claim 32, wherein the cancerous cells are the result of a cancer selected from the group consisting of gastric cancer, prostate cancer, colon cancer, breast cancer, Non-Hodgkin's lymphoma, ovarian cancer, sarcoma, lung cancer, leukemia, myeloma, testicular cancer, cervical cancer, pancreatic cancer, head and neck cancer, rectal cancer, and brain cancer.

### Claim 45 (depends on 32)

The method of claim 32, comprising the step of administering to said patient an amount of radiotherapy configured to treat the cancerous cells.

### Claim 46 (depends on 1, 32)

The method of claim 32, wherein step of administering the therapeutically effective amount of the compound of claim 1 comprises administering an additional therapeutic agent selected from the group consisting of bortezomib, dexamethasone, or a combination thereof.
